Display options
Cite
Xing X, Zhou X, Yang Y, et al. The impact of body composition parameters on severe toxicities in patients with locoregionally advanced nasopharyngeal carcinoma undergoing neoadjuvant chemotherapy. Ann Transl Med. 2021;9(14):1180doi: 10.21037/atm-21-3412.
Xing, X., Zhou, X., Yang, Y., Li, Y., Hu, C., & Shen, C. (2021). The impact of body composition parameters on severe toxicities in patients with locoregionally advanced nasopharyngeal carcinoma undergoing neoadjuvant chemotherapy. Annals of translational medicine, 9(14), 1180. https://doi.org/10.21037/atm-21-3412
Xing, Xing, et al. "The impact of body composition parameters on severe toxicities in patients with locoregionally advanced nasopharyngeal carcinoma undergoing neoadjuvant chemotherapy." Annals of translational medicine vol. 9,14 (2021): 1180. doi: https://doi.org/10.21037/atm-21-3412
Xing X, Zhou X, Yang Y, Li Y, Hu C, Shen C. The impact of body composition parameters on severe toxicities in patients with locoregionally advanced nasopharyngeal carcinoma undergoing neoadjuvant chemotherapy. Ann Transl Med. 2021 Jul;9(14):1180. doi: 10.21037/atm-21-3412. PMID: 34430621; PMCID: PMC8350723.
Copy Download .nbib Format: NLM
Share it on

Ann Transl Med. 2021 Jul;9(14):1180. doi: 10.21037/atm-21-3412.

The impact of body composition parameters on severe toxicities in patients with locoregionally advanced nasopharyngeal carcinoma undergoing neoadjuvant chemotherapy.

Annals of translational medicine

Xing Xing, Xin Zhou, Youqi Yang, Yujiao Li, Chaosu Hu, Chunying Shen

Affiliations

  1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  3. Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.

PMID: 34430621 PMCID: PMC8350723 DOI: 10.21037/atm-21-3412

Abstract

BACKGROUND: Neoadjuvant chemotherapy (NACT) treatment in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) can lead to considerable toxicity. Loss of skeletal muscle mass showed relevance with increased chemotherapy-related toxicity and poor survival in various cancer types, but its significance in NPC remains unclear. This study aimed to investigate the relationship between body composition parameters and the incidence of NACT toxicity in LA-NPC patients.

METHODS: Ninety-six LA-NPC patients were retrospectively enrolled. All patients had pre-treatment abdominal computed tomography (CT) images to exclude distant metastasis. Lean body mass (LBM, kg) was estimated based on cross-sectional muscle area at the third lumbar vertebra (L3) level on CT, and skeletal muscle index (SMI, cm

RESULTS: Of the 96 patients, 81.2% received the docetaxel + cisplatin (TP) regimen, and the rest received the gemcitabine + cisplatin (GP) regimen. Males had more LBM and a higher SMI at baseline, and females received a markedly higher dose of docetaxel and gemcitabine per kg LBM (P<0.001). With a cutoff value of 52.7 cm

CONCLUSIONS: LA-NPC patients with lower SMI and higher dose of docetaxel per kg LBM are more likely to suffer from severe treatment-related toxicity. Higher docetaxel dose per kg LBM is a prominent predictor for severe neutropenia, but not for NACT response. LBM showed good potential in toxicity risk prediction and dose determination.

2021 Annals of Translational Medicine. All rights reserved.

Keywords: Locoregionally advanced nasopharyngeal carcinoma (LA-NPC); body composition; lean body mass (LBM); neoadjuvant chemotherapy (NACT); skeletal muscle index (SMI)

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/atm-21-3412). The authors have no conflicts of interest to declare.

References

  1. J Clin Oncol. 2016 Apr 20;34(12):1339-44 - PubMed
  2. Ann Transl Med. 2020 Mar;8(5):223 - PubMed
  3. Nutr Rev. 1991 Jun;49(6):163-75 - PubMed
  4. Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006 - PubMed
  5. Radiother Oncol. 2020 Jun;147:103-110 - PubMed
  6. Cancer Res. 1958 Aug;18(7):853-6 - PubMed
  7. J Clin Oncol. 2013 Apr 20;31(12):1539-47 - PubMed
  8. Nutrients. 2020 Mar 12;12(3): - PubMed
  9. Ther Adv Med Oncol. 2020 Aug 18;12:1758835920947612 - PubMed
  10. Eur J Cancer. 2002 Sep;38(13):1677-84 - PubMed
  11. Lancet Oncol. 2016 Nov;17(11):1509-1520 - PubMed
  12. Oral Oncol. 2020 Feb;101:104530 - PubMed
  13. Pharmacol Ther. 2019 Apr;196:135-159 - PubMed
  14. J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):298-304 - PubMed
  15. J Thorac Oncol. 2015 Dec;10(12):1795-9 - PubMed
  16. Medicine (Baltimore). 2016 Mar;95(13):e3164 - PubMed
  17. J Appl Physiol (1985). 2004 Dec;97(6):2333-8 - PubMed
  18. Sci Rep. 2018 Jul 27;8(1):11369 - PubMed
  19. Radiat Oncol. 2019 Sep 11;14(1):166 - PubMed
  20. J Gastric Cancer. 2017 Mar;17(1):74-87 - PubMed
  21. Surg Gynecol Obstet. 1957 Feb;104(2):183-9 - PubMed

Publication Types